Eveliqure

Description

Eveliqure develops live attenuated and engineered bacterial vaccine candidates to prevent diarrhoeal diseases, including a first-generation candidate (ShigETEC) designed to protect against Shigella and enterotoxigenic Escherichia coli.

Eveliqure is located in the Vienna ecosystem.

Related

• ElarisElaris develops next‑generation vaccines to prevent Clostridioides difficile infection.
• MinervaXMinervaX is developing a prophylactic Group B Streptococcal (GBS) vaccine, AlpN GBS, that works as a clinical-stage immunization product…
• ActiTrexxActiTrexx develops therapies based on activated regulatory T cells for autoimmune and autoinflammatory diseases, including ATreg/Actileucel…
• BelynticBelyntic develops T-Fender vaccines that use self-adjuvant, self-aggregating synthetic long peptides, combined with AI-based prediction, to…
• Bavarian NordicBavarian Nordic researches, develops, and manufactures life-saving vaccines, maintains product and pipeline materials, and operates process…
• CysbioCysbio builds engineered bacterial cell factories and proprietary bioprocesses to produce amino acids, sulfated biochemicals and…
• CytuvaxCytuvax develops cancer immunotherapy and vaccines for viral and bacterial pathogens, using depot-attached cytokines as immune-stimulating…
• ATXA TherapeuticsATXA Therapeutics develops selective small-molecule thromboxane receptor (TP) antagonists, including lead candidate NTP42, to treat…
• ElogiumElogium develops probiotic feed additives based on proprietary Bacillus subtilis strains to reduce pathogens in farm animals, targeting…